ES2440919T3 - Nuevos polipéptidos con afinidad por HER2 - Google Patents

Nuevos polipéptidos con afinidad por HER2 Download PDF

Info

Publication number
ES2440919T3
ES2440919T3 ES08864430.7T ES08864430T ES2440919T3 ES 2440919 T3 ES2440919 T3 ES 2440919T3 ES 08864430 T ES08864430 T ES 08864430T ES 2440919 T3 ES2440919 T3 ES 2440919T3
Authority
ES
Spain
Prior art keywords
her2
amino acid
polypeptide
polypeptide according
affibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08864430.7T
Other languages
English (en)
Spanish (es)
Inventor
Lars Abrahmsén
Nina Herne
Joachim Feldwisch
Christofer Lendel
Vladimir Tolmachev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Application granted granted Critical
Publication of ES2440919T3 publication Critical patent/ES2440919T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08864430.7T 2007-12-21 2008-12-22 Nuevos polipéptidos con afinidad por HER2 Active ES2440919T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150395A EP2072525A1 (en) 2007-12-21 2007-12-21 New polypeptides having affinity for HER2
EP07150395 2007-12-21
PCT/EP2008/068167 WO2009080810A1 (en) 2007-12-21 2008-12-22 New polypeptides having affinity for her2

Publications (1)

Publication Number Publication Date
ES2440919T3 true ES2440919T3 (es) 2014-01-31

Family

ID=39148791

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08864430.7T Active ES2440919T3 (es) 2007-12-21 2008-12-22 Nuevos polipéptidos con afinidad por HER2

Country Status (11)

Country Link
US (2) US8501909B2 (enExample)
EP (2) EP2072525A1 (enExample)
JP (2) JP5913807B2 (enExample)
CN (2) CN104327179A (enExample)
AU (1) AU2008339976B2 (enExample)
CA (1) CA2709915C (enExample)
DK (1) DK2235044T3 (enExample)
ES (1) ES2440919T3 (enExample)
HK (1) HK1202880A1 (enExample)
PL (1) PL2235044T3 (enExample)
WO (1) WO2009080810A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20120165650A1 (en) * 2010-12-22 2012-06-28 General Electric Company Her2 binders
WO2010120514A2 (en) * 2009-03-31 2010-10-21 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
WO2011110515A1 (en) * 2010-03-08 2011-09-15 Affibody Ab Immunoglobulin g fc region binding polypeptide
DE102010026061A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
TWI486617B (zh) * 2010-10-21 2015-06-01 Iner Aec Executive Yuan 一種測定對鎝（Ｔｃ－９９ｍ）與錸（Ｒｅ－１８６、Ｒｅ－１８８）具有穩定錯合力之含硫螯合劑在凍晶劑中之含量與均一性的固態樣品分析技術
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2654803B1 (en) * 2010-12-22 2021-08-18 General Electric Company Radiolabeled her2-binding peptide conjugates
US9061080B2 (en) 2010-12-22 2015-06-23 Ge Healthcare Limited HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
NZ612327A (en) * 2010-12-22 2015-03-27 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
WO2014053586A1 (en) * 2012-10-05 2014-04-10 Affibody Ab Her3 binding polypeptides
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
KR20160055728A (ko) * 2013-06-27 2016-05-18 지이 헬쓰케어 리미티드 Her2 결합제의 용도
US9982022B2 (en) * 2013-08-28 2018-05-29 Affibody Ab Binding polypeptides having a mutated scaffold
WO2015028558A1 (en) 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
PT3604333T (pt) 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
CN104292308B (zh) * 2014-08-22 2017-09-15 广州安辰医药科技有限公司 肿瘤抗原环肽
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
JP6622814B2 (ja) * 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ イメージングのための新規ｐｄ−ｌ１結合ポリペプチド
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2021122729A1 (en) 2019-12-18 2021-06-24 Bracco Imaging Spa Anti-her2 polypeptides derivatives as new diagnostic molecular probes
CN114829388B (zh) * 2019-12-18 2026-02-03 伯拉考成像股份公司 抗her2多肽衍生物作为新的诊断分子探针
EP3842452A1 (en) 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Scaffold proteins and therapeutic nanoconjugates based on nidogen
CN112220931B (zh) * 2020-10-16 2022-03-08 上海交通大学 用于肿瘤主动靶向治疗的亲和体-细胞毒素偶联物及其纳米颗粒、制备方法、应用
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用
CN116063397B (zh) * 2022-07-04 2025-05-02 中国药科大学 一类靶向her2蛋白的多肽及其在制备多肽偶联药物中的应用
CN117430670A (zh) * 2022-07-20 2024-01-23 中国科学院上海药物研究所 一种her2靶向肽分子及其应用
CN119677787A (zh) 2022-08-10 2025-03-21 兴和株式会社 亲和体微胞药物复合体
WO2025158010A1 (en) 2024-01-25 2025-07-31 Affibody Ab Her2-binding polypeptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE0301987D0 (sv) * 2003-07-04 2003-07-04 Affibody Ab New polypeptide
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
US8937047B2 (en) 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2

Also Published As

Publication number Publication date
JP2011507497A (ja) 2011-03-10
CN104327179A (zh) 2015-02-04
US8501909B2 (en) 2013-08-06
JP2015061838A (ja) 2015-04-02
US8883120B2 (en) 2014-11-11
EP2235044B1 (en) 2013-10-09
CA2709915A1 (en) 2009-07-02
AU2008339976A1 (en) 2009-07-02
DK2235044T3 (da) 2014-01-06
JP5913807B2 (ja) 2016-04-27
US20130280164A1 (en) 2013-10-24
CN101952302B (zh) 2014-11-12
US20110020223A1 (en) 2011-01-27
AU2008339976B2 (en) 2013-05-30
HK1202880A1 (en) 2015-10-09
PL2235044T3 (pl) 2014-03-31
CN101952302A (zh) 2011-01-19
WO2009080810A1 (en) 2009-07-02
EP2235044A1 (en) 2010-10-06
CA2709915C (en) 2016-05-24
EP2072525A1 (en) 2009-06-24
HK1153207A1 (en) 2012-03-23

Similar Documents

Publication Publication Date Title
CA2709915C (en) New polypeptides having affinity for her2
ES2319426T3 (es) Polipeptidos que presentan afinidad de union por her-2.
ES2676403T3 (es) Polipéptidos
Tolmachev Imaging of HER-2 overexpression in tumors for guiding therapy
Tran et al. 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors
CA2822693C (en) Radiolabled her2 binding peptides
CA3118223A1 (en) Dual mode 18f-labelled theranostic compounds and uses thereof
Sabahnoo et al. New small 99mTc-labeled peptides for HER2 receptor imaging
Perols et al. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules
Altai et al. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re
Altai et al. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA
EP2661284A1 (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound
Honarvar et al. Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging
Yoon et al. Bispecific Her2× cotinine antibody in combination with cotinine–(histidine) 2–iodine for the pre-targeting of Her2-positive breast cancer xenografts
Rosik et al. Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging
CN1816563B (zh) 对her2具有结合亲和力的多肽
Ekblad et al. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules
US20240124533A1 (en) New her2-binding polypeptide
JP7795810B2 (ja) プレターゲットイメージングおよび治療用ｐｎａプローブ
Larkina et al. The position of 99mTc-HYNIC and the molecular design of the DARPin G3 constructs influence the selection of an imaging tracer to detect expression in HER2-expressing tumors
HK1153207B (en) New polypeptides having affinity for her2
WO2024181930A1 (en) Asparaginyl peptide ligase-mediated radiolabelling of single-domain antibodies
TW202545983A (zh) 新穎多肽
WO2014013016A1 (en) Method for determining the her2 status of a malignancy
WO2011110490A1 (en) Process for the production of radioactively labelled scfv antibody fragments, kits and compositions